Waters (WAT) has just been removed from several Russell growth and defensive indexes, a technical event that can influence how index-linked funds hold or sell the stock in coming months.

Despite Waters being dropped from several Russell indexes, recent price action has been relatively firm, with a 90-day share price return of 24.67% and a 1-year total shareholder return of 8.30%. This suggests momentum has picked up after a softer year to date.

If you are reassessing your watchlist after Waters' index changes, it could be a good moment to broaden your search with the 20 top founder-led companies

With Waters stock up 24.67% over 90 days, trading at $379.29 and implying a 23.17% intrinsic discount alongside a modest gap to analyst targets, you need to ask: is there real value here, or is future growth already priced in?

Most Popular Narrative: 5.6% Undervalued

On the most followed narrative, Waters screens as modestly undervalued, with a fair value estimate of $401.78 versus the recent close at $379.29, and that gap rests on some ambitious growth and profitability assumptions.

The planned combination with BD's Biosciences and Diagnostic Solutions business is expected to accelerate entry into biologics, precision medicine, and cell/gene therapy markets, segments with expanding analytical needs, unlocking new addressable markets and providing a multi-year revenue synergy opportunity, directly impacting future revenues and EPS growth.

Curious what kind of revenue ramp, margin lift, and future earnings multiple sit behind that fair value for Waters? The narrative leans on rapid top line expansion, fatter profit margins, and a rich earnings valuation years out. The full story spells out how those ingredients combine into today’s price gap.

Result: Fair Value of $401.78 (UNDERVALUED)

However, this Waters narrative depends heavily on the smooth integration of BD Biosciences and Diagnostic Solutions, as well as on funding in academic and government markets not weakening further.

Another View: What Multiples Say About Waters

While the SWS DCF model points to Waters trading at a 23.2% discount to its estimated future cash flows, the picture looks different when you just look at earnings. Waters trades on a P/E of 82.8x, compared with a fair ratio of 32.3x, peers at 33x, and the Global Life Sciences industry at 37.1x, which suggests a rich earnings valuation. This raises the question of whether this represents a quality premium that holds or a gap that eventually closes.

See what the numbers say about this price, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

Given the mix of optimism and concern around Waters, it makes sense to look past headlines and work through the numbers yourself. If you want a structured view of both the upsides and the potential red flags investors are focused on, start with these 2 key rewards and 3 important warning signs

Looking for more investment ideas beyond Waters?

If Waters is already on your radar, do not stop there. Broaden your opportunity set with a few focused stock ideas built from the Simply Wall St Screener.

• Target consistent income by checking out companies tagged as potential yield anchors using the 7 dividend fortresses.
• Hunt for quality at a reasonable price by scanning companies that combine solid fundamentals with attractive pricing in the screener containing 18 high quality undiscovered gems.
• Prioritize capital preservation and steadier returns by reviewing resilient companies highlighted in the 74 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.